Similar articles

• Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.

  Das M. Das M. Expert Rev Cardiovasc Ther. 2009 Feb;7(2):181-95. doi: 10.1586/14779072.7.2.181. Expert Rev Cardiovasc Ther. 2009. PMID: 19210214 Review.
• Role of implantable cardioverter defibrillators in non-ischaemic dilated cardiomyopathy.

  Scott PA, Roberts PR. Scott PA, et al. Postgrad Med J. 2010 Feb;86(1012):116-22. doi: 10.1136/pgmj.2009.088518. Postgrad Med J. 2010. PMID: 20145061 Review.
• Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.

  You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. You JJ, et al. Am Heart J. 2007 Nov;154(5):899-907. doi: 10.1016/j.ahj.2007.06.026. Am Heart J. 2007. PMID: 17967596
• How should we cost ICD therapy?

  Fox DJ, Davidson NC, Fitzpatrick AP. Fox DJ, et al. Int J Cardiol. 2007 May 16;118(1):1-3. doi: 10.1016/j.ijcard.2006.05.054. Epub 2007 Jan 25. Int J Cardiol. 2007. PMID: 17258335 No abstract available.
• [Usefulness of the implantable cardiodefibrillator (ICD) in the prevention of sudden death. Results of evidence based medicine].

  González CM. González CM. Arch Cardiol Mex. 2007 Apr-Jun;77 Suppl 2:S2-44-S2-46. Arch Cardiol Mex. 2007. PMID: 17972377 Review. Spanish.